XCath is a medical device company pioneering neuro-endovascular surgical robotics. Its lead system, Iris, is a robotic platform designed to navigate catheters and guidewires through the vasculature to reach targets deep in the brain, enabling minimally invasive treatment of conditions such as strokes and aneurysms. Complementing the robot, XCath develops steerable neurovascular guidewires engineered for precise navigation through the complex, tortuous vessels of the neurovascular system.
Founded in 2017 and led by Nicholas Drysdale and Eduardo Fonseca, XCath operates from campuses in Houston, Texas, and Pangyo, South Korea. The company's mission centers on improving global outcomes in neurovascular care, an area where outcomes are highly time-sensitive and access to specialized expertise is uneven. By enabling robotic and potentially remote navigation, XCath aims to bring advanced neurovascular intervention to more patients and more hospitals.
In November 2025 XCath reported successful first-in-human procedures using its Iris robotic system to treat patients with complex brain aneurysms, a milestone the company described as only the second time in history that a surgical robot had been used in an intracranial neurovascular intervention. This clinical validation is significant in a field where the gap between bench technology and real procedures is large and difficult to bridge.
XCath secured $30 million in Series C funding announced in early 2026, bringing total funding since inception to $92 million. The round was co-led by Crescent Enterprises and by Dr. Fred Moll, chairman of XCath's board and a renowned figure in surgical robotics. The capital supports continued development and commercialization of the Iris system and the company's broader goal of widening access to advanced neurovascular treatment worldwide.